Table 2 Patient safety data through week 9
| Â | Placebo | Indigo naturalis |
|---|---|---|
Patients treated, n | 8 | 16 |
Patients with >1 adverse event, n (%) | 4 (50.0) | 7 (44.0) |
Average duration of follow-up (weeks) | 9.14 | 9.13 |
Average exposure (weeks) | 8.16 | 8.13 |
Common adverse events, n (%) | ||
 Pruritus | 1 (12.5) | 4 (25.0) |
 Rash | 0 (0.0) | 2 (12.5) |
 Nasopharyngitis | 0 (0.0) | 2 (12.5) |
 Abdominal distension | 0 (0.0) | 1 (6.3) |
 Constipation | 0 (0.0) | 1 (6.3) |
 Cough | 0 (0.0) | 1 (6.3) |
 Dizziness | 0 (0.0) | 1 (6.3) |
 Oropharyngeal pain | 0 (0.0) | 1 (6.3) |
 Gout | 1 (12.5) | 0 (0.0) |
 Allergies | 1 (12.5) | 0 (0.0) |
 Pyrexia | 1 (12.5) | 0 (0.0) |